You're right to be concerned. Recent regulatory actions have highlighted serious cardiovascular risks associated with certain medications. This is a complex and rapidly evolving area, so let's break down the most significant alerts, drug withdrawals, and what they mean for your safety.
Critical Disclaimer: I am an AI, not a doctor. This information is for educational purposes and should not replace professional medical advice. If you are taking any of the medications discussed, do not stop taking them without first consulting your healthcare provider. Abruptly stopping certain medications can be extremely dangerous.Medication side effects
🚨 Major Drug Safety Alerts & Withdrawals
Several medications have recently come under intense scrutiny due to links to life-threatening conditions like blood clots, stroke, and heart attack. Here are the most significant developments:
1. JAK Inhibitors: Increased Risk of Heart Attack, Stroke, Blood Clots & Death
A class of drugs used for chronic inflammation, known as Janus kinase (JAK) inhibitors, now carries the FDA's most prominent "Boxed Warning" due to serious safety concerns .
Affected Drugs:
Xeljanz / Xeljanz XR (tofacitinib) – for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis
Olumiant (baricitinib) – for rheumatoid arthritis
Rinvoq (upadaclitinib) – for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis
The Risk: A large safety trial for Xeljanz showed an increased risk of serious heart-related events (heart attack and stroke), cancer, blood clots, and death compared to another class of arthritis drugs called TNF blockers . While Olumiant and Rinvoq haven't been studied in the same way, the FDA considers that they may have similar risks because they work similarly . The European Medicines Agency (EMA) also confirmed an increased risk of blood clots in the lungs and deep veins (DVT) with Xeljanz, especially at higher doses .
What This Means for Patients: If you are taking one of these medications, your doctor should evaluate your risk factors. The risk is particularly high for patients who are current or past smokers, have other cardiovascular risk factors, or have a history of heart problems or blood clots . This does not necessarily mean you should stop the medication, but you must have an informed discussion with your doctor about your personal risks and benefits.
2. Andexxa (Anticoagulant Reversal Agent) – Withdrawn from U.S. Market
In a major development in late 2025, AstraZeneca voluntarily withdrew the drug Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) from the U.S. market after the FDA determined its risks outweigh its benefits .
